Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Fedyanin on Future Treatment Landscape of CRC

December 20th 2016

Mikhail Fedyanin, MD, PhD, Russian Academy of Medical Science, discusses future approaches for the treatment of patients with colorectal cancer (CRC).

Mutational Complexity Reflects Treatment Challenges for Hepatocellular Carcinoma

December 19th 2016

The growing incidence of primary liver cancer in the United States poses a great therapeutic challenge.

Dr. Marshall on Next Steps Following Y-90 in Liver-Metastatic CRC

December 17th 2016

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the next steps following the findings from the phase III SIRFLOX trial, which explored the addition of selective internal radiation therapy (SIRT), using Y-90 resin microspheres, to FOLFOX-based first-line chemotherapy in patients with liver-dominant metastatic colorectal cancer (mCRC).

Dr. Bekaii-Saab on the Expansion of Treatment Options in Colorectal Cancer

December 16th 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the recent expansion of treatment options available for patients with colorectal cancer.

Targeted Therapy Makes Inroads in Gastroesophageal Cancer

December 15th 2016

Gastroesophageal cancer (GEC) is a complex disease, encompassing cancers with different histological and molecular subtypes. Growing insight into the molecular biology of GEC is poised to change the treatment landscape for this disease, although many questions remain unanswered.

Dr. Venook on Immunotherapy Potential in Colorectal Cancer

December 15th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the potential that immunotherapy may have in the treatment of patients with colorectal cancer.

Lancet Data Highlight OS Benefit for Regorafenib in HCC

December 9th 2016

Regorafenib (Stivarga) has demonstrated the first survival benefit for a systemic therapy in the second-line setting for patients with advanced hepatocellular carcinoma (HCC) who have progressed on sorafenib (Nexavar), according to results from the phase III RESORCE trial published in The Lancet.1

DNA Repair Defects Emerge as a New Category for Anticancer Therapies

December 2nd 2016

A coordinated network of signaling pathways works to protect the cell from the toxic effects of DNA damage.

Tumor Location Insights in mCRC Challenge Standard of Care

December 2nd 2016

It is highly probable that molecular profiling is the key to more precise treatments, as well as prediction of outcomes in metastatic colorectal cancer.

Dr. Tanios Bekaii-Saab on Sequencing Questions in mCRC

November 29th 2016

Tanios Bekaii-Saab, MD, a professor of Medicine at Mayo Clinic, discusses sequencing regorafenib (Stivarga) and TAS-102 (Lonsurf) in metastatic colorectal cancer (mCRC).

FDA Grants Priority Review to Pembrolizumab for MSI-H Cancer

November 29th 2016

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab for previously treated patients with advanced microsatellite instability-high cancer.

Dr. Marshall on the Safety Profile of Y-90 in Colorectal Cancer

November 29th 2016

John L. Marshall, MD, chief, Division of Hematology and Oncology, Medstar Georgetown University Hospital, and director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers, discusses the safety profile of Yttrium-90, particularly when combined with capecitabine as a treatment for patients with liver-dominant metastatic colorectal cancer.

Dr. John L. Marshall on Y-90 in Colorectal Cancer

November 23rd 2016

Dr. Bekaii-Saab Compares Toxicities of Regorafenib and TAS-102 in Colorectal Cancer

November 22nd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, compares the toxicity profiles of regorafenib and TAS-102, which are both used to treat patients with metastatic colorectal cancer.

Cetuximab Benefit, Tumor Sidedness Impact Still Unclear in mCRC

November 21st 2016

Alan P. Venook, MD, discusses key issues in metastatic colorectal cancer, including tumor sidedness and the conflicting data regarding the precise benefit of cetuximab in the frontline setting.

Dr. Jordi Bruix on Efficacy and Safety of Regorafenib in HCC After Sorafenib

November 17th 2016

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer (BCLC) at University of Barcelona, discusses the efficacy, safety, and quality-of-life with regorafenib, a novel second-line agent that is currently being considered for approval by the FDA for second-line systemic therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib.

Dr. Ghassan Abou-Alfa on Impact of Second-Line Regorafenib in HCC

November 17th 2016

Ghassan K. Abou-Alfa, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the impact of the phase III RESORCE trial, which demonstrated that regorafenib improved survival over placebo for patients with hepatocellular carcinoma (HCC) that progressed on sorafenib.

Tumor Burden Limits Liver Transplant Feasibility for HCC

November 17th 2016

Researchers have uncovered an upper limit in tumor burden after which there is a lower probability of successfully downstaging patients with hepatocellular carcinoma for liver transplantation.

Expert Anticipates Significant Shift in Clinical Practice for Liver-Dominant mCRC

November 17th 2016

An overall survival analysis of 3 randomized controlled trials exploring Yttrium-90 (Y-90) resin microspheres may demonstrate noteworthy survival benefits for patients with liver-dominant metastatic colorectal cancer receiving first-line FOLFOX6 with or without bevacizumab plus Y-90 resin microspheres.

Dr. Suzanne L. Topalian on Immunotherapy Biomarkers in CRC

November 17th 2016

Suzanne L. Topalian, MD, professor of Surgery, Johns Hopkins Medicine, discuses novel immunotherapy biomarkers in colorectal cancer (CRC).